Gene · 685
BTC: betacellulin
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. BTC: betacellulin. Genes, record 685. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/685
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35070 | Probetacellulin | 178 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents68
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026067859 A | 2026-04-21 | 156 | P35070 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11311 | P35070 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 1760 | P35070 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 11783 | P35070 | Espacenet |
| JP 2025138725 A | 2025-09-25 | 2685 | P35070 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 607 | P35070 | Espacenet |
| EP 4606428 A2 | 2025-08-27 | 15 | P35070 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 607 | P35070 | Espacenet |
| EP 4587837 A1 | 2025-07-23 | 55 | P35070 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 1760 | P35070 | Espacenet |
1 to 10 of 68
See all 68 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,104
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BTC papers | Newest fiscal year |
|---|---|---|---|
| P30CA068485 | Cancer Center Support Grant | 13 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 5 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 5 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 4 | 2025 |
| P30DK020593 | Vanderbilt Diabetes Research Center | 4 | 2025 |
| T32CA009582 | Biochemical and Chemical Training for Cancer Research | 4 | 2025 |
| P30CA023168 | Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,104Source NIH's project files
See all 1,104 nih grantsPapers1,437
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Exploring and validating hub genes associated with atopic dermatitis through weighted gene co-expression network analysis and machine learning. | Medicine (Baltimore) | 2026 | 42629711 | PubTator, text mining | PubMed |
| Detecting Unusual Trading Patterns on Cryptocurrency Exchanges by Means of Complexity Measures. | Entropy (Basel) | 2026 | 42511413 | PubTator, text mining | PubMed |
| A review of epidermal growth factor receptor ligands in glucose homeostasis. | Front Endocrinol (Lausanne) | 2026 | 42290844 | PubTator, text mining | PubMed |
| Growth factor betacellulin can stimulate human granulosa cell functions and promote gonadotropin actions. | Mol Biol Rep | 2026 | 42240693 | PubTator, text mining | PubMed |
| HNRNPDL facilitates the advancement of non-small cell lung carcinoma via modulating the alternative splicing of the BTC gene. | Immunobiology | 2026 | 41861445 | PubTator, text mining | PubMed |
| Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer. | J Immunother Cancer | 2026 | 41825935 | PubTator, text mining | PubMed |
| Maternal docosahexaenoic acid and eicosapentaenoic acid supplementation: effects and mechanisms on lipid metabolism in the offspring. | Front Nutr | 2026 | 41798834 | PubTator, text mining | PubMed |
| Dynamic dual regulation of amphiregulin in liver pathophysiology: balancing regeneration and disease progression via the EGFR axis. | Front Med (Lausanne) | 2026 | 41788718 | PubTator, text mining | PubMed |
| The ADAM Family of Proteases: Structure, Substrates, and Roles in Liver Diseases. | Int J Mol Sci | 2026 | 41751763 | PubTator, text mining | PubMed |
| In vitro cytotoxicity of medicinal plants used in prostate cancer management in Africa: a systematic review. | Trop Med Health | 2026 | 41709315 | PubTator, text mining | PubMed |
1 to 10 of 1,437
See all 1,437 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/685
GET https://conductscience.org/api/genes/v1/685/patents?page=2